Table 1.

Secondary antigen candidates identified in patients from IMPACT, using ProtoArray

Antigen annotationProtoArray data
Antigen symbolAntigen nameAverage fold changePFDR (%)Rank by average fold change
LGALS3Galectin-34.942.84E−102.05E−041
CACNG1Calcium channel, voltage-dependent, gamma subunit 14.833.60E−072.69E−022
ANPEPAminopeptidase N (CD13)4.735.69E−086.85E−033
FBXO6F-box protein 63.881.62E−082.68E−034
ECE1Endothelin converting enzyme 13.423.73E−063.26E−025
ERASEmbryonic stem-cell–expressed Ras2.724.16E−063.26E−0215
TSPAN13Tetraspanin 132.661.73E−063.26E−0217
PAPProstatic acid phosphatase2.551.18E−063.15E−0223
LGALS8/PCTA-1Galectin-8/prostate carcinoma tumor antigen 12.192.89E−055.09E−0268
KRASKirsten rat sarcoma viral oncogene homolog2.103.20E−063.26E−0299
KLK2/hK2Kallikrien-related peptidase 22.043.67E−055.50E−02138

NOTE: Increase in serum levels of IgGs against 10 candidate secondary antigens at week 10 after completion of sipuleucel-T treatment, as measured by ProtoArray. Data for PAP (primary antigen) are shown for reference. Columns indicate (for serum level of anti-antigen IgG posttreatment): average fold increase posttreatment, P value from moderated paired t test (limma), estimated FDR (% FDR, Benjamini and Hochberg procedure), and rank of antigens by average fold increase in corresponding serum IgG level.